Hyderabad: The full commercial launch that is much delayed from the Covid-19 Vaksin Russia Sputnik V finally begins with Panacea Biotec who started the supply of the second dose component (human adenovirus serotype 5 – AD5) from the vaccine.
Panacea Biotec has announced the first shipping supply, of 1 million dosages, from the second dose component of Sputnik V for sale in India which will be distributed by the Russian direct investment fund partner (RDIF) Mitra Reddy’s Labs.
“This is the first batch of the second component produced at our facilities at Himachal Pradesh and supplied in India.
The company accepted the required permissions from the Central Medicine Center (CDL), Kasauli, on August 31,” Panacea Biotec said.
With this, Dr.
Reddy’s laboratory, who has struggled to increase supply to a private hospital because of the illness in the second dose, on Tuesday that it has begun to increase the availability of vaccines nationally.
“Dr.
Reddy’s has initiated the supply of the first dose component to partner hospitals throughout India followed by the second dose of equal component.
With more batch of second dose components to follow the manufacturing site we expect this momentum and supply to continue,” said a spokesman Reddy told toi.
The launch came more than four months after Sputnik V accepted EUA in mid-April.
Dr.
Reddy has announced mid-June as a deadline for commercial launch but failed to do so because only 4.5 lakh second dose dose and 31.5 lakh dose of the first dose component (AD26) from Russia.
Two doses must be given 21 separate days.
Sputnik V commercial launch begins
